Article
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.
Molecular cancer therapeutics - 1 Jun 2022
Adashek Jacob J, Menta Arjun K, Reddy Neha K, Desai Aakash P, Roszik Jason, Subbiah Vivek
Abstract excerpt
BRAF plus MEK inhibitor combinations are currently FDA-approved for melanoma, non-small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF inhibition in BRAF V600-mutated colorectal cancer has prevented its tissue-agnostic drug development. We reviewed the AACR GENIE database for the prevalence of BRAF V600 mutations across tumor types. We reviewed the literature for case...
Topics
- Adult
- Carcinoma, Non-Small-Cell Lung
- Child
- Humans
- Lung Neoplasms
- Mitogen-Activated Protein Kinase Kinases
- Mutation
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins B-raf
- Skin Neoplasms
- Thyroid Neoplasms